Biomarkers to Differentiate Acute Chest Syndrome From Vaso-Occlusive Crisis in Children With Sickle Cell Disease.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-11-05 DOI:10.1111/ejh.14342

Karen Wang, Nelida Olave, Saurabh Aggarwal, Joo-Yeun Oh, Rakesh P Patel, A K M Fazlur Rahman, Jeffrey Lebensburger, Ammar Saadoon Alishlash

{"title":"Biomarkers to Differentiate Acute Chest Syndrome From Vaso-Occlusive Crisis in Children With Sickle Cell Disease.","authors":"Karen Wang, Nelida Olave, Saurabh Aggarwal, Joo-Yeun Oh, Rakesh P Patel, A K M Fazlur Rahman, Jeffrey Lebensburger, Ammar Saadoon Alishlash","doi":"10.1111/ejh.14342","DOIUrl":null,"url":null,"abstract":"Background: Acute Chest Syndrome (ACS) is the leading cause of death in children with sickle cell disease (SCD) in the US-about half of the children who develop ACS present initially with pain.Methods: Here, we studied biomarkers to differentiate ACS from vaso-occlusive crises (VOC) in children with SCD who presented with pain to the emergency department (ED). We conducted a prospective cohort study of consecutive patients who presented to the ED with pain and were discharged with ACS or VOC between March, 2017 and February, 2020.Results: We identified 7 patients with ACS and 19 patients with VOC. The two groups were comparable in age and sex. All patients with ACS had asthma versus 42% of the VOC group. The ACS group had lower weight and BMI z-scores. Patients with ACS compared to VOC had significantly higher respiratory rates, lower O2 saturation, and longer hospital stays. They also had higher white blood cell count, glucose level (> 99 mg/dL), anion gap (> 9 mEq/L), sPLA2 (> 7 pg/mL), IFN-γ (> 17.8 pg/mL), IL-10 (1.54 pg/mL), and IL-12 (> 0.5 pg/mL) levels.Conclusions: We identified biomarkers associated with ACS development in children with SCD presenting with pain that allow for earlier ACS interventions to reduce mortality and morbidity.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ejh.14342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute Chest Syndrome (ACS) is the leading cause of death in children with sickle cell disease (SCD) in the US-about half of the children who develop ACS present initially with pain.

Methods: Here, we studied biomarkers to differentiate ACS from vaso-occlusive crises (VOC) in children with SCD who presented with pain to the emergency department (ED). We conducted a prospective cohort study of consecutive patients who presented to the ED with pain and were discharged with ACS or VOC between March, 2017 and February, 2020.

Results: We identified 7 patients with ACS and 19 patients with VOC. The two groups were comparable in age and sex. All patients with ACS had asthma versus 42% of the VOC group. The ACS group had lower weight and BMI z-scores. Patients with ACS compared to VOC had significantly higher respiratory rates, lower O₂ saturation, and longer hospital stays. They also had higher white blood cell count, glucose level (> 99 mg/dL), anion gap (> 9 mEq/L), sPLA2 (> 7 pg/mL), IFN-γ (> 17.8 pg/mL), IL-10 (1.54 pg/mL), and IL-12 (> 0.5 pg/mL) levels.

Conclusions: We identified biomarkers associated with ACS development in children with SCD presenting with pain that allow for earlier ACS interventions to reduce mortality and morbidity.

查看原文本刊更多论文

区分镰状细胞病儿童急性胸部综合征和血管闭塞性危象的生物标志物

背景：急性胸部综合征（ACS）是导致美国镰状细胞病（SCD）患儿死亡的主要原因--约半数发生 ACS 的患儿最初表现为疼痛。方法：在此，我们研究了区分急诊科（ED）疼痛患儿 ACS 和血管闭塞性危象（VOC）的生物标志物。我们对 2017 年 3 月至 2020 年 2 月期间因疼痛到急诊科就诊并因 ACS 或 VOC 而出院的连续患者进行了前瞻性队列研究：我们发现了 7 名 ACS 患者和 19 名 VOC 患者。两组患者的年龄和性别相当。所有 ACS 患者均患有哮喘，而 42% 的 VOC 组患者患有哮喘。ACS 组患者的体重和体重指数 z 值较低。与 VOC 相比，ACS 患者的呼吸频率明显更高，氧饱和度更低，住院时间更长。他们的白细胞计数、葡萄糖水平（> 99 mg/dL）、阴离子间隙（> 9 mEq/L）、sPLA2（> 7 pg/mL）、IFN-γ（> 17.8 pg/mL）、IL-10（1.54 pg/mL）和 IL-12（> 0.5 pg/mL）水平也更高：结论：我们发现了与出现疼痛的 SCD 儿童 ACS 发展相关的生物标志物，这些生物标志物可用于早期 ACS 干预，以降低死亡率和发病率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464